Shin John I, Leggett Andrew R, Berg Ari R, Harris Colin B, Merchant Aziz M, Vives Michael J
Department of Orthopaedics, Rutgers University New Jersey Medical School, Newark, NJ, USA
Department of Orthopaedics, Rutgers University New Jersey Medical School, Newark, NJ, USA.
Int J Spine Surg. 2023 Aug;17(4):579-586. doi: 10.14444/8476. Epub 2023 Jul 17.
For patients with back pain from osteoporotic vertebral compression fractures (VCFs), vertebral augmentation remains the most utilized surgical intervention. Previous studies report 30-day readmission and mortality rates of up to 10% and 2%, respectively. These studies, however, have included patients with pathologic fractures and combined patients in different admission settings. We undertook the current study to address such shortcomings, which make risk stratification and appropriate counseling difficult.
Four consecutive years of the National Surgical Quality Improvement Program database were queried. Patients who underwent vertebral augmentation for osteoporotic VCFs were divided into 3 groups: (1) outpatient group (defined as patients with same-day discharge), (2) inpatient group (defined as those who were admitted postoperatively), and (3) preprocedure hospitalized group (defined as those who were already inpatient or were at acute/intermediate care facilities and transferred). Postoperative 30-day complications and readmission rates were compared between different groups and examined using multivariate analyses.
A total of 1023 patients underwent outpatient surgery; 503 were admitted on the day of surgery; and 149 patients were already in-hospital or were transferred from other facility. Mortality rates were 0.68%, 0.60%, and 2.68%, and readmission rates were 6.26%, 6.76%, and 12.8%, for outpatient, inpatient, and preprocedure hospitalization cohorts, respectively. Multivariate analyses identified preprocedure hospitalization as an independent risk factor for urinary tract infection (UTI; OR = 3.98, 95% CI = 1.41-11.20, = 0.028), pneumonia (OR = 19.69, 95% CI = 3.81-101.65, < 0.001), readmission (OR = 1.86, 95% CI = 1.06-3.26, = 0.032), and mortality (OR = 4.49, 95% CI = 1.22-16.53, = 0.024).
Our findings suggest that published rates of complications and mortality are substantially impacted by the cohort of patients who are already hospitalized or transferred from other facilities. Such patients are at a higher risk of UTI, pneumonia, readmission, and mortality. Conversely, we show that a relatively healthy patient being offered outpatient same-day augmentation has a readmission risk 40% lower and a mortality risk 3 times lower than previously reported.
对于因骨质疏松性椎体压缩骨折(VCF)导致背痛的患者,椎体强化术仍然是最常用的外科干预措施。既往研究报告30天再入院率和死亡率分别高达10%和2%。然而,这些研究纳入了病理性骨折患者以及不同入院情况的合并患者。我们开展本研究以解决这些缺陷,这些缺陷使得风险分层和适当的咨询变得困难。
查询了国家外科质量改进计划数据库连续四年的数据。因骨质疏松性VCF接受椎体强化术的患者被分为3组:(1)门诊组(定义为当日出院的患者),(2)住院组(定义为术后入院的患者),以及(3)术前住院组(定义为已住院或在急性/中级护理机构并被转诊的患者)。比较不同组之间的术后30天并发症和再入院率,并使用多因素分析进行检验。
共有1023例患者接受了门诊手术;503例在手术当天入院;149例患者已住院或从其他机构转诊而来。门诊、住院和术前住院队列的死亡率分别为0.68%、0.60%和2.68%,再入院率分别为6.26%、6.76%和12.8%。多因素分析确定术前住院是尿路感染(UTI;OR = 3.98,95%CI = 1.41 - 11.20,P = 0.028)、肺炎(OR = 19.69,95%CI = 3.81 - 101.65,P < 0.001)、再入院(OR = 1.86,95%CI = 1.06 - 3.26,P = 0.032)和死亡(OR = 4.49,95%CI = 1.22 - 16.53,P = 0.024)的独立危险因素。
我们的研究结果表明,已发表的并发症和死亡率受已住院或从其他机构转诊的患者队列的显著影响。此类患者发生UTI、肺炎、再入院和死亡的风险更高。相反,我们表明,接受门诊当日强化术的相对健康患者的再入院风险比先前报告的低40%,死亡风险低3倍。